Use of immunomodulators in combination with infliximab in Crohn's disease: time for a reappraisal?

Lancet Gastroenterol Hepatol

Translational Gastroenterology Unit, Nuffield Department of Experimental Medicine, University of Oxford, Oxford, UK.

Published: May 2024

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2468-1253(23)00406-5DOI Listing

Publication Analysis

Top Keywords

immunomodulators combination
4
combination infliximab
4
infliximab crohn's
4
crohn's disease
4
disease time
4
time reappraisal?
4
immunomodulators
1
infliximab
1
crohn's
1
disease
1

Similar Publications

Patient-derived NMDAR mAbs combined with single-particle cryo-electron microscopy reveal multiple GluN1 epitopes and distinct functional effects.

View Article and Find Full Text PDF

Current diagnosis and treatment of rheumatoid arthritis (RA) is still challenging. More than one-third of patients with RA could not be accurately diagnosed because of lacking biomarkers. Our recent study reported that scavenger receptor-A (SR-A) is a biomarker for RA, especially for anticyclic citrullinated peptide antibody (anti-CCP)-negative RA.

View Article and Find Full Text PDF

Immune events such as infection, vaccination, and a combination of the two result in distinct time-dependent antibody responses in affected individuals. These responses and event prevalence combine non-trivially to govern antibody levels sampled from a population. Time-dependence and disease prevalence pose considerable modeling challenges that need to be addressed to provide a rigorous mathematical underpinning of the underlying biology.

View Article and Find Full Text PDF

Limited research into the tumor immune microenvironment (TIME) for bladder urothelial carcinoma (BUC), particularly the neglect of the intratumoral microbiota, has hindered the development of immunotherapies targeting BUC. Here, we collect 401 patients with BUC with host transcriptome samples and matched tumor microbiome samples from The Cancer Genome Atlas database. Besides, two independent BUC cohorts receiving immunotherapy were obtained.

View Article and Find Full Text PDF

Targeting immune checkpoints on myeloid cells: current status and future directions.

Cancer Immunol Immunother

January 2025

Department of General Surgery, Shengjing Hospital of China Medical University, ShenyangLiaoning Province, 110004, China.

Myeloid cells accumulate extensively in most tumors and play a critical role in immunosuppression of the tumor microenvironment (TME). Like T cells, myeloid cells also express immune checkpoint molecules, which induce the immunosuppressive phenotype of these cells. In this review, we summarize the tumor-promoting function and immune checkpoint expression of four types of myeloid cells: macrophages, neutrophils, dendritic cells, and myeloid-derived suppressor cells, which are the main components of the TME.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!